US 12,150,750 B2
D-glucose and its analogs as tracers to assess the glucose transporter function on blood-cerebrospinal fluid barrier and the functioning of the brain lymphatic system
Jiadi Xu, Timonium, MD (US); Peter Van Zijl, Hanover, MD (US); Lin Chen, Baltimore, MD (US); Kannie Wai Yan Chan, Hong Kong (CN); and Jianpan Huang, Hong Kong (CN)
Assigned to The Johns Hopkins University, Baltimore, MD (US); Kennedy Krieger Institute, Baltimore, MD (US); and City Iniversity of Hong Kong, Kowloon (HK)
Appl. No. 17/918,031
Filed by The Johns Hopkins University, Baltimore, MD (US)
PCT Filed Apr. 7, 2021, PCT No. PCT/US2021/026217
§ 371(c)(1), (2) Date Oct. 10, 2022,
PCT Pub. No. WO2021/207382, PCT Pub. Date Oct. 14, 2021.
Claims priority of provisional application 63/006,952, filed on Apr. 8, 2020.
Prior Publication US 2023/0126413 A1, Apr. 27, 2023
Int. Cl. A61B 5/055 (2006.01); G01R 33/565 (2006.01); G01R 33/483 (2006.01)
CPC A61B 5/055 (2013.01) [G01R 33/565 (2013.01); G01R 33/4833 (2013.01)] 16 Claims
OG exemplary drawing
 
1. A method of assessing the brain lymphatic or glymphatic system and the glucose transporter function on blood-cerebrospinal fluid barrier (BCSFB) of a subject using D-glucose or a D-glucose analog, comprising:
generating a spatial map of water magnetic resonance (MR) signals that are sensitized to changes in D-glucose or a D-glucose analog in cerebrospinal fluid (CSF) of the subject;
observing the spatial map at one or more time points before, one or more time points during, and one or more time points after, raising the blood level of the D-glucose or a D-glucose analog in the subject CSF;
detecting a difference between the MR signals of the spatial map before, during, and after raising the blood level of D-glucose or a D-glucose analog; and
ascertaining a physiological parameter associated with the brain lymphatic or glymphatic system and the glucose transporter function on BCSFB of the subject based on the detected difference.